LOCALLY ADVANCED PROSTATE CANCER
Clinical trials for LOCALLY ADVANCED PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED PROSTATE CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to boost prostate cancer cure rates
Disease control Recruiting nowThis study tests whether taking two medications (relugolix and enzalutamide) before standard radiation or surgery can improve cure rates for men with high-risk locally advanced prostate cancer. About 46 participants will take the drugs for up to 24 months, then receive standard t…
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated May 26, 2026 11:17 UTC
-
Could a targeted drug replace hormone therapy in prostate cancer?
Disease control Recruiting nowThis study tests whether adding the drug Pluvicto to targeted radiation can lower the chance of cancer coming back in men with advanced prostate cancer, while avoiding the side effects of standard hormone therapy. About 45 men will receive Pluvicto before and after radiation, wit…
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Angela Y. Jia, MD PhD • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Can a precise radiation boost and fewer sessions beat prostate cancer relapse?
Disease control Recruiting nowThis study aims to improve treatment for men with high-risk prostate cancer by testing two changes to standard radiotherapy: giving a higher dose directly to the tumor (a focal boost) and reducing the number of treatment sessions from 20 to 12. About 1,016 participants will be ra…
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated May 22, 2026 13:52 UTC